Targeting the epigenome for treatment of cancer

DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis

(2011) A. T. Nguyen et al.   BLOOD

Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement

(2011) Ruben A. Mesa et al.   CANCER

TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis

(2011) Cyril Quivoron et al.   CANCER CELL

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

(2011) Scott R. Daigle et al.   CANCER CELL

MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L

(2011) Kathrin M. Bernt et al.   CANCER CELL

Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation

(2011) Kelly Moran-Crusio et al.   CANCER CELL

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

KDM2A represses transcription of centromeric satellite repeats and maintains the heterochromatic state

(2011) David Frescas et al.   CELL CYCLE

Aberrations of EZH2 in Cancer

(2011) A. Chase et al.   CLINICAL CANCER RESEARCH

Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas

(2011) Anastasios Stathis et al.   CLINICAL CANCER RESEARCH

Genes methylated by DNA methyltransferase 3b are similar in mouse intestine and human colon cancer

(2011) Eveline J. Steine et al.   JOURNAL OF CLINICAL INVESTIGATION

Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression

(2011) Lukas D. Wartman et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

(2011) Mark Kirschbaum et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

(2011) Giuseppe Giaccone et al.   JOURNAL OF CLINICAL ONCOLOGY

When Signaling Kinases Meet Histones and Histone Modifiers in the Nucleus

(2011) Sung Hee Baek   MOLECULAR CELL

CREBBP mutations in relapsed acute lymphoblastic leukaemia

(2011) Charles G. Mullighan et al.   NATURE

Inactivating mutations of acetyltransferase genes in B-cell lymphoma

(2011) Laura Pasqualucci et al.   NATURE

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

(2011) Ryan D. Morin et al.   NATURE

BRCA1 tumour suppression occurs via heterochromatin-mediated silencing

(2011) Quan Zhu et al.   NATURE

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

(2011) Ignacio Varela et al.   NATURE

The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset

(2011) Craig J. Ceol et al.   NATURE

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

(2011) Marcus Bantscheff et al.   NATURE BIOTECHNOLOGY

A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells

(2011) Masoud Vedadi et al.   Nature Chemical Biology

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder

(2011) Yaoting Gui et al.   NATURE GENETICS

Exome sequencing identifies GRIN2A as frequently mutated in melanoma

(2011) Xiaomu Wei et al.   NATURE GENETICS

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

(2011) Meng Li et al.   NATURE GENETICS

Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia

(2011) Xiao-Jing Yan et al.   NATURE GENETICS

The von Hippel–Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C

(2011) X Niu et al.   ONCOGENE

Loss of lysine-specific demethylase 1 nonautonomously causes stem cell tumors in the Drosophila ovary

(2011) S. Eliazer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation

(2011) L. Wang et al.   SCIENCE

Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis

(2011) F. Fang et al.   Science Translational Medicine

Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation

(2010) D. B. Yap et al.   BLOOD

Mechanisms of leukemogenesis by MLL fusion proteins

(2010) Rolf Marschalek   BRITISH JOURNAL OF HAEMATOLOGY

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

(2010) Ruben Niesvizky et al.   CANCER

MLL fusions: Pathways to leukemia

(2010) Han Liu et al.   CANCER BIOLOGY & THERAPY

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Cooperative Epigenetic Modulation by Cancer Amplicon Genes

(2010) Lixin Rui et al.   CANCER CELL

Hdac3 Is Essential for the Maintenance of Chromatin Structure and Genome Stability

(2010) Srividya Bhaskara et al.   CANCER CELL

H3K9 Histone Methyltransferase G9a Promotes Lung Cancer Invasion and Metastasis by Silencing the Cell Adhesion Molecule Ep-CAM

(2010) M.-W. Chen et al.   CANCER RESEARCH

Nitric Oxide-Mediated Histone Hyperacetylation in Oral Cancer: Target for a Water-Soluble HAT Inhibitor, CTK7A

(2010) Mohammed Arif et al.   CHEMISTRY & BIOLOGY

Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer

(2010) Sonia Mulero-Navarro et al.   Epigenetics

The histone demethylase UTX enables RB-dependent cell fate control

(2010) J. K. Wang et al.   GENES & DEVELOPMENT

Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors

(2010) Salvador Rodriguez-Nieto et al.   HUMAN MUTATION

G9a and Glp Methylate Lysine 373 in the Tumor Suppressor p53

(2010) Jing Huang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

(2010) Sean J. Whittaker et al.   JOURNAL OF CLINICAL ONCOLOGY

Design, Synthesis, Enzyme-Inhibitory Activity, and Effect on Human Cancer Cells of a Novel Series of Jumonji Domain-Containing Protein 2 Histone Demethylase Inhibitors

(2010) Shohei Hamada et al.   JOURNAL OF MEDICINAL CHEMISTRY

Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study

(2010) Anne M. Traynor et al.   Journal of Thoracic Oncology

Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

(2010) Suresh S. Ramalingam et al.   Journal of Thoracic Oncology

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)

(2010) Gregory A. Otterson et al.   Journal of Thoracic Oncology

Nanaomycin A Selectively Inhibits DNMT3B and Reactivates Silenced Tumor Suppressor Genes in Human Cancer Cells

(2010) D. Kuck et al.   MOLECULAR CANCER THERAPEUTICS

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

(2010) Myunggon Ko et al.   NATURE

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

(2010) Gillian L. Dalgliesh et al.   NATURE

Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification

(2010) Shinsuke Ito et al.   NATURE

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

Epigenetic modifications as therapeutic targets

(2010) Theresa K Kelly et al.   NATURE BIOTECHNOLOGY

BRD7 is a candidate tumour suppressor gene required for p53 function

(2010) Jarno Drost et al.   NATURE CELL BIOLOGY

LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease

(2010) Dean S. Griffiths et al.   NATURE CELL BIOLOGY

Chemical phylogenetics of histone deacetylases

(2010) James E Bradner et al.   Nature Chemical Biology

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

(2010) Ryan D Morin et al.   NATURE GENETICS

Therapy with azanucleosides for myelodysplastic syndromes

(2010) Alfonso Quintás-Cardama et al.   Nature Reviews Clinical Oncology

ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas

(2010) Kimberly C. Wiegand et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNMT3AMutations in Acute Myeloid Leukemia

(2010) Timothy J. Ley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents

(2010) M. Namdar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma

(2010) Siân Jones et al.   SCIENCE

The Genetic Landscape of the Childhood Cancer Medulloblastoma

(2010) D. W. Parsons et al.   SCIENCE

An Integrated Genomic and Epigenomic Approach Predicts Therapeutic Response to Zebularine in Human Liver Cancer

(2010) J. B. Andersen et al.   Science Translational Medicine

Histone demethylases in development and disease

(2010) Marianne Terndrup Pedersen et al.   TRENDS IN CELL BIOLOGY

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

(2010) Julia M. Wagner et al.   Clinical Epigenetics

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

(2009) L. R. Molife et al.   ANNALS OF ONCOLOGY

The Biology of Chromatin Remodeling Complexes

(2009) Cedric R. Clapier et al.   Annual Review of Biochemistry

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

(2009) W. Fiskus et al.   BLOOD

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

(2009) F. P. S. Santos et al.   BLOOD

The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer

(2009) Tyler Lahusen et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

(2009) Kristie A. Blum et al.   BRITISH JOURNAL OF HAEMATOLOGY

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

(2009) Michael Dickinson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)

(2009) Deborah Bradley et al.   CANCER

A New Class of Quinoline-Based DNA Hypomethylating Agents Reactivates Tumor Suppressor Genes by Blocking DNA Methyltransferase 1 Activity and Inducing Its Degradation

(2009) J. Datta et al.   CANCER RESEARCH

Lysine-Specific Demethylase 1 Is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for Therapy

(2009) J. H. Schulte et al.   CANCER RESEARCH

Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology

(2009) Soyoung Lim et al.   CARCINOGENESIS

LSD1 Is a Subunit of the NuRD Complex and Targets the Metastasis Programs in Breast Cancer

(2009) Yan Wang et al.   CELL

Epigenetic Modifiers: Basic Understanding and Clinical Development

(2009) R. L. Piekarz et al.   CLINICAL CANCER RESEARCH

Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes

(2009) M. T. Voso et al.   CLINICAL CANCER RESEARCH

Genomic Analysis Using High-Density Single Nucleotide Polymorphism-Based Oligonucleotide Arrays and Multiplex Ligation-Dependent Probe Amplification Provides a Comprehensive Analysis of INI1/SMARCB1 in Malignant Rhabdoid Tumors

(2009) E. M. Jackson et al.   CLINICAL CANCER RESEARCH

Targeting DNA Methylation

(2009) J.-P. J. Issa et al.   CLINICAL CANCER RESEARCH

Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes

(2009) Y. Huang et al.   CLINICAL CANCER RESEARCH

The Histone Demethylase RBP2 Is Overexpressed in Gastric Cancer and Its Inhibition Triggers Senescence of Cancer Cells

(2009) Jiping Zeng et al.   GASTROENTEROLOGY

Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS

(2009) M. Barradas et al.   GENES & DEVELOPMENT

The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence

(2009) K. Agger et al.   GENES & DEVELOPMENT

A phase 2 study of vorinostat in acute myeloid leukemia

(2009) E. W. Schaefer et al.   HAEMATOLOGICA

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

(2009) Evanthia Galanis et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma

(2009) Axel Hauschild et al.   MELANOMA RESEARCH

Biosynthetic Enzyme GMP Synthetase Cooperates with Ubiquitin-Specific Protease 7 in Transcriptional Regulation of Ecdysteroid Target Genes

(2009) J. A. van der Knaap et al.   MOLECULAR AND CELLULAR BIOLOGY

DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation

(2009) T. B. Miranda et al.   MOLECULAR CANCER THERAPEUTICS

Epigenetic Silencing of the RASSF1A Tumor Suppressor Gene through HOXB3-Mediated Induction of DNMT3B Expression

(2009) Rajendra Kumar Palakurthy et al.   MOLECULAR CELL

Protein Arginine Methylation in Mammals: Who, What, and Why

(2009) Mark T. Bedford et al.   MOLECULAR CELL

JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

(2009) Mark A. Dawson et al.   NATURE

Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger

(2009) Gang G. Wang et al.   NATURE

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

(2009) Gijs van Haaften et al.   NATURE GENETICS

Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma

(2009) Paul A Northcott et al.   NATURE GENETICS

Acquired mutations in TET2 are common in myelodysplastic syndromes

(2009) Saskia M C Langemeijer et al.   NATURE GENETICS

Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294

(2009) Yanqi Chang et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Mutation inTET2in Myeloid Cancers

(2009) François Delhommeau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer

(2009) G Liu et al.   ONCOGENE

The SWI/SNF complex and cancer

(2009) D Reisman et al.   ONCOGENE

Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma

(2009) M. Berdasco et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia

(2009) S.-S. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genetic dissection of histone deacetylase requirement in tumor cells

(2009) M. Haberland et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions

(2009) C. Choudhary et al.   SCIENCE

Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1

(2009) M. Tahiliani et al.   SCIENCE

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma

(2008) M. Crump et al.   ANNALS OF ONCOLOGY

DACT3 Is an Epigenetic Regulator of Wnt/β-Catenin Signaling in Colorectal Cancer and Is a Therapeutic Target of Histone Modifications

(2008) Xia Jiang et al.   CANCER CELL

HDAC expression and clinical prognosis in human malignancies

(2008) Wilko Weichert   CANCER LETTERS

The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis

(2008) Y.-S. Lee et al.   CANCER RESEARCH

Targeted Knockout of BRG1 Potentiates Lung Cancer Development

(2008) S. Glaros et al.   CANCER RESEARCH

Defining a Chromatin Pattern that Characterizes DNA-Hypermethylated Genes in Colon Cancer Cells

(2008) K. M. McGarvey et al.   CANCER RESEARCH

Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin

(2008) D. S. Schrump et al.   CLINICAL CANCER RESEARCH

Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo

(2008) W. Weichert et al.   CLINICAL CANCER RESEARCH

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

(2008) T. H. Luu et al.   CLINICAL CANCER RESEARCH

Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers

(2008) F. Braiteh et al.   CLINICAL CANCER RESEARCH

Histone Deacetylase 8 in Neuroblastoma Tumorigenesis

(2008) I. Oehme et al.   CLINICAL CANCER RESEARCH

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

(2008) Susan C. Modesitt et al.   GYNECOLOGIC ONCOLOGY

Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)

(2008) Robert P. Whitehead et al.   INVESTIGATIONAL NEW DRUGS

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

(2008) Johan Vansteenkiste et al.   INVESTIGATIONAL NEW DRUGS

Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma

(2008) Jennifer A. Woyach et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues

(2008) Ke Long Jin et al.   Journal of Gynecologic Oncology

CHD5 , a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas

(2008) Tomoyuki Fujita et al.   JNCI-Journal of the National Cancer Institute

Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis

(2008) Wilko Weichert et al.   LANCET ONCOLOGY

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas

(2008) S Balasubramanian et al.   LEUKEMIA

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis

(2008) A Quintás-Cardama et al.   LEUKEMIA

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science

(2008) O Kilpivaara et al.   LEUKEMIA

The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation

(2008) Jing Wang et al.   NATURE GENETICS

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

(2008) Michael Haberland et al.   NATURE REVIEWS GENETICS

Downregulation of Histone H3 Lysine 9 Methyltransferase G9a Induces Centrosome Disruption and Chromosome Instability in Cancer Cells

(2008) Yutaka Kondo et al.   PLoS One

Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers

(2008) R. J. Leary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epigenetic Reprogramming by Adenovirus e1a

(2008) R. Ferrari et al.   SCIENCE

Drosophila Stem Cells Share a Common Requirement for the Histone H2B Ubiquitin Protease Scrawny

(2008) M. Buszczak et al.   SCIENCE

Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)

(2007) P.W. Wijermans et al.   LEUKEMIA RESEARCH